Study of Hepalatide(L47) at Phase Ib in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Hepatitis B, Chronic
Interventions
DRUG

Hepalatide

There are three cohorts as follows 4.2mg, 6.3mg, 8.4mg. At each dose level, healthy volunteers will be received treatment drug by abdominal subcutaneous injection once a day for seven days and will be monitored for 3 days.

DRUG

Placebo

There are three cohorts as follows 4.2mg, 6.3mg, 8.4mg. At each dose level, healthy volunteers will be received control drug by abdominal subcutaneous injection once a day for seven days and will be monitored for 3 days.

Trial Locations (1)

Unknown

302 Military Hospital, Beijing

All Listed Sponsors
lead

Shanghai HEP Pharmaceutical Co., Ltd.

INDUSTRY

NCT03023787 - Study of Hepalatide(L47) at Phase Ib in Healthy Volunteers | Biotech Hunter | Biotech Hunter